Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ABBOTT LABORATORIESABT · Entity 2314 | EXECUTIVE VICE PRESIDENT | February 28, 2023 | March 03, 2023 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ABBOTT LABORATORIES
Report date February 28, 2023 · Filed March 03, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common shares without par valueSEC Table I · non-derivative | Direct | 118,380 |
Ending reported balance
After 2023-03-01 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2023-02-28 · Tax withholding · Disposed 6,859 · Balance 119,323 Row 2 · 2023-03-01 · Sale · Disposed 943 · Balance 118,380 |
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 01, 2023 Filed Mar 3, 2023 00:36 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 943 | $100.70 | $94,960.10 |
DisclosureSEC source: 0001415889-23-003908 · form4-03032023_120322.xml · nonDerivative · entry 2 Ginascol John F · CIK 0001778075 · EXECUTIVE VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 118,380 Read SEC document |
| February 28, 2023 Filed Mar 3, 2023 00:36 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Tax withholdingCommon shares without par value | 6,859 | $99.77 | $684,322.43 |
DisclosureSEC source: 0001415889-23-003908 · form4-03032023_120322.xml · nonDerivative · entry 1 Ginascol John F · CIK 0001778075 · EXECUTIVE VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 119,323 Read SEC document |
| February 17, 2023 Filed Feb 22, 2023 23:56 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantOption (right to buy) · Derivative | 56,275 | $0.00 Strike: $106.24 | $0.00 |
DisclosureSEC source: 0001415889-23-003053 · form4-02222023_110237.xml · derivative · entry 2 Ginascol John F · CIK 0001778075 · EXECUTIVE VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,275 Underlying: Common Shares · 56,275 shares Expires 2033-02-16 F2 · security: Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 18,758 on February 17, 2024, 18,758 on February 17, 2025, and 18,759 on February 17, 2026. Read SEC document |
| February 17, 2023 Filed Feb 22, 2023 23:56 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantCommon shares without par value | 14,270 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-23-003053 · form4-02222023_110237.xml · nonDerivative · entry 1 Ginascol John F · CIK 0001778075 · EXECUTIVE VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 126,182 F1 · shares: These shares represent a performance-based restricted stock award under the Abbott Laboratories 2017 Incentive Stock Program. The award has a 3-year term, with no more than 1/3 of the award vesting in any one year upon Abbott reaching a minimum return on equity target. The award includes the right to have shares withheld for tax purposes. Read SEC document |
| December 13, 2022 Filed Dec 15, 2022 22:26 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 11,000 | $112.32 | $1,235,520.00 |
DisclosureSEC source: 0001415889-22-012600 · form4-12152022_101206.xml · nonDerivative · entry 1 Ginascol John F · CIK 0001778075 · EXECUTIVE VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 111,912 Read SEC document |
| June 03, 2022 Filed Jun 7, 2022 21:14 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Tax withholdingCommon shares without par value | 1,768 | $117.51 | $207,757.68 |
DisclosureSEC source: 0001415889-22-006223 · form4-06072022_020602.xml · nonDerivative · entry 1 Ginascol John F · CIK 0001778075 · EXECUTIVE VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 122,912 Read SEC document |
| February 28, 2022 Filed Mar 3, 2022 00:47 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Tax withholdingCommon shares without par value | 5,876 | $122.41 | $719,281.16 |
DisclosureSEC source: 0001415889-22-002193 · form4-03022022_040330.xml · nonDerivative · entry 1 Ginascol John F · CIK 0001778075 · EXECUTIVE VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 125,045 Read SEC document |
| February 18, 2022 Filed Feb 24, 2022 01:15 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantOption (right to buy) · Derivative | 80,380 | $0.00 Strike: $117.58 | $0.00 |
DisclosureSEC source: 0001415889-22-001738 · form4-02232022_050221.xml · derivative · entry 2 Ginascol John F · CIK 0001778075 · EXECUTIVE VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 80,380 Underlying: Common Shares · 80,380 shares Expires 2032-02-17 F2 · security: Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 26,793 on February 18, 2023, 26,793 on February 18, 2024, and 26,794 on February 18, 2025. Read SEC document |
| February 18, 2022 Filed Feb 24, 2022 01:15 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantCommon shares without par value | 17,247 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-22-001738 · form4-02232022_050221.xml · nonDerivative · entry 1 Ginascol John F · CIK 0001778075 · EXECUTIVE VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 130,921 F1 · shares: These shares represent a performance-based restricted stock award under the Abbott Laboratories 2017 Incentive Stock Program. The award has a 3-year term, with no more than 1/3 of the award vesting in any one year upon Abbott reaching a minimum return on equity target. The award includes the right to have shares withheld for tax purposes. Read SEC document |
| October 27, 2021 Filed Oct 27, 2021 22:45 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionOption (right to buy) · Derivative | 45,709 | $0.00 Strike: $47.00 | $0.00 |
DisclosureSEC source: 0001415889-21-004998 · form4-10272021_031009.xml · derivative · entry 3 Ginascol John F · CIK 0001778075 · EXECUTIVE VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares · 45,709 shares Expires 2025-02-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: Stock option granted pursuant to the Abbott Laboratories 2009 Incentive Stock Program, in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| October 27, 2021 Filed Oct 27, 2021 22:45 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Tax withholdingCommon shares without par value | 29,588 | $128.13 | $3,791,110.44 |
DisclosureSEC source: 0001415889-21-004998 · form4-10272021_031009.xml · nonDerivative · entry 2 Ginascol John F · CIK 0001778075 · EXECUTIVE VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 113,674 Read SEC document |
| October 27, 2021 Filed Oct 27, 2021 22:45 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionCommon shares without par value | 45,709 | $47.00 | $2,148,323.00 |
DisclosureSEC source: 0001415889-21-004998 · form4-10272021_031009.xml · nonDerivative · entry 1 Ginascol John F · CIK 0001778075 · EXECUTIVE VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 143,262 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 03, 2021 Filed Jun 7, 2021 21:31 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Tax withholdingCommon shares without par value | 1,768 | $106.90 | $188,999.20 |
DisclosureSEC source: 0001415889-21-002830 · form4-06072021_020640.xml · nonDerivative · entry 1 Ginascol John F · CIK 0001778075 · EXECUTIVE VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 97,553 Read SEC document |
| March 01, 2021 Filed Mar 3, 2021 00:30 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 352 | $120.61 | $42,454.72 |
DisclosureSEC source: 0001415889-21-001206 · form4-03022021_040308.xml · nonDerivative · entry 2 Ginascol John F · CIK 0001778075 · EXECUTIVE VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 99,321 Read SEC document |
| March 01, 2021 Filed Mar 3, 2022 00:47 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 365 | $118.16 | $43,128.47 |
DisclosureSEC source: 0001415889-22-002193 · form4-03022022_040330.xml · nonDerivative · entry 2 Ginascol John F · CIK 0001778075 · EXECUTIVE VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 124,680 Read SEC document |
| February 26, 2021 Filed Mar 3, 2021 00:30 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Tax withholdingCommon shares without par value | 4,736 | $121.58 | $575,802.88 |
DisclosureSEC source: 0001415889-21-001206 · form4-03022021_040308.xml · nonDerivative · entry 1 Ginascol John F · CIK 0001778075 · EXECUTIVE VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 99,673 Read SEC document |
| February 19, 2021 Filed Feb 23, 2021 23:53 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantOption (right to buy) · Derivative | 78,966 | $0.00 Strike: $124.04 | $0.00 |
DisclosureSEC source: 0001415889-21-000893 · form4-02232021_030243.xml · derivative · entry 2 Ginascol John F · CIK 0001778075 · EXECUTIVE VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 78,966 Underlying: Common Shares · 78,966 shares Expires 2031-02-18 F2 · security: Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 26,322 on February 19, 2022, 26,322 on February 19, 2023, and 26,322 on February 19, 2024. Read SEC document |
| February 19, 2021 Filed Feb 23, 2021 23:53 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantCommon shares without par value | 15,406 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-21-000893 · form4-02232021_030243.xml · nonDerivative · entry 1 Ginascol John F · CIK 0001778075 · EXECUTIVE VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 104,409 F1 · shares: These shares represent a performance-based restricted stock award under the Abbott Laboratories 2017 Incentive Stock Program. The award has a 3-year term, with no more than 1/3 of the award vesting in any one year upon Abbott reaching a minimum return on equity target. The award includes the right to have shares withheld for tax purposes. Read SEC document |
| September 01, 2020 Filed Sep 3, 2020 22:33 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionOption (right to buy) · Derivative | 39,953 | $0.00 Strike: $44.40 | $0.00 |
DisclosureSEC source: 0001179110-20-009571 · edgar.xml · derivative · entry 7 Ginascol John F · CIK 0001778075 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common shares · 39,953 shares Expires 2027-02-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: Employee stock option granted pursuant to the Abbott Laboratories 2009 Incentive Stock Program, in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| September 01, 2020 Filed Sep 3, 2020 22:33 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionOption (right to buy) · Derivative | 20,133 | $0.00 Strike: $38.40 | $0.00 |
DisclosureSEC source: 0001179110-20-009571 · edgar.xml · derivative · entry 6 Ginascol John F · CIK 0001778075 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common shares · 20,133 shares Expires 2026-02-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: Employee stock option granted pursuant to the Abbott Laboratories 2009 Incentive Stock Program, in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| September 01, 2020 Filed Sep 3, 2020 22:33 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionOption (right to buy) · Derivative | 12,012 | $0.00 Strike: $47.00 | $0.00 |
DisclosureSEC source: 0001179110-20-009571 · edgar.xml · derivative · entry 5 Ginascol John F · CIK 0001778075 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,709 Underlying: Common shares · 12,012 shares Expires 2025-02-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: Employee stock option granted pursuant to the Abbott Laboratories 2009 Incentive Stock Program, in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| September 01, 2020 Filed Sep 3, 2020 22:33 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Tax withholdingCommon shares without par value | 47,772 | $109.47 | $5,229,600.84 |
DisclosureSEC source: 0001179110-20-009571 · edgar.xml · nonDerivative · entry 4 Ginascol John F · CIK 0001778075 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 89,003 Read SEC document |
| September 01, 2020 Filed Sep 3, 2020 22:33 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionCommon shares without par value | 39,953 | $44.40 | $1,773,913.20 |
DisclosureSEC source: 0001179110-20-009571 · edgar.xml · nonDerivative · entry 3 Ginascol John F · CIK 0001778075 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 136,775 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 01, 2020 Filed Sep 3, 2020 22:33 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionCommon shares without par value | 20,133 | $38.40 | $773,107.20 |
DisclosureSEC source: 0001179110-20-009571 · edgar.xml · nonDerivative · entry 2 Ginascol John F · CIK 0001778075 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 96,822 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 01, 2020 Filed Sep 3, 2020 22:33 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionCommon shares without par value | 12,012 | $47.00 | $564,564.00 |
DisclosureSEC source: 0001179110-20-009571 · edgar.xml · nonDerivative · entry 1 Ginascol John F · CIK 0001778075 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 76,689 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 03, 2020 Filed Jun 5, 2020 21:02 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Tax withholdingCommon shares without par value | 1,768 | $92.62 | $163,752.16 |
DisclosureSEC source: 0001179110-20-007035 · edgar.xml · nonDerivative · entry 1 Ginascol John F · CIK 0001778075 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 64,677 Read SEC document |
| April 21, 2020 Filed Apr 24, 2020 01:41 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionOption (right to buy) · Derivative | 63,200 | $0.00 Strike: $38.40 | $0.00 |
DisclosureSEC source: 0001179110-20-005071 · edgar.xml · derivative · entry 4 Ginascol John F · CIK 0001778075 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,133 Underlying: Common shares · 63,200 shares Expires 2026-02-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · security: Employee stock option granted pursuant to the Abbott Laboratories 2009 Incentive Stock Program, in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| April 21, 2020 Filed Apr 24, 2020 01:41 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 39,234 | $96.26 | $3,776,629.53 |
DisclosureSEC source: 0001179110-20-005071 · edgar.xml · nonDerivative · entry 3 Ginascol John F · CIK 0001778075 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 66,445 F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $96.10 to $96.44, inclusive. The reporting person undertakes to provide to Abbott Laboratories, any security holder of Abbott Laboratories, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| April 21, 2020 Filed Apr 24, 2020 01:41 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 23,966 | $95.57 | $2,290,421.03 |
DisclosureSEC source: 0001179110-20-005071 · edgar.xml · nonDerivative · entry 2 Ginascol John F · CIK 0001778075 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 105,679 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $95.10 to $96.095, inclusive. The reporting person undertakes to provide to Abbott Laboratories, any security holder of Abbott Laboratories, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| April 21, 2020 Filed Apr 24, 2020 01:41 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionCommon shares without par value | 63,200 | $38.40 | $2,426,880.00 |
DisclosureSEC source: 0001179110-20-005071 · edgar.xml · nonDerivative · entry 1 Ginascol John F · CIK 0001778075 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 129,645 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 02, 2020 Filed Mar 3, 2020 22:20 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 5,600 | $77.58 | $434,448.00 |
DisclosureSEC source: 0001179110-20-002899 · edgar.xml · nonDerivative · entry 3 Ginascol John F · CIK 0001778075 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 66,445 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $77.56 to $77.599, inclusive. The reporting person undertakes to provide to Abbott Laboratories, any security holder of Abbott Laboratories, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| March 02, 2020 Filed Mar 3, 2020 22:20 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 1,006 | $77.89 | $78,357.34 |
DisclosureSEC source: 0001179110-20-002899 · edgar.xml · nonDerivative · entry 2 Ginascol John F · CIK 0001778075 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 72,045 Read SEC document |
| February 28, 2020 Filed Mar 3, 2020 22:20 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Tax withholdingCommon shares without par value | 2,246 | $79.19 | $177,860.74 |
DisclosureSEC source: 0001179110-20-002899 · edgar.xml · nonDerivative · entry 1 Ginascol John F · CIK 0001778075 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 73,051 Read SEC document |
| February 21, 2020 Filed Feb 25, 2020 22:18 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantOption (right to buy) · Derivative | 114,940 | $0.00 Strike: $87.72 | $0.00 |
DisclosureSEC source: 0001179110-20-002268 · edgar.xml · derivative · entry 2 Ginascol John F · CIK 0001778075 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 114,940 Underlying: Common shares · 114,940 shares Expires 2030-02-20 F2 · security: Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 38,313 on February 21, 2021, 38,313 on February 21, 2022, and 38,314 on February 21, 2023. Read SEC document |
| February 21, 2020 Filed Feb 25, 2020 22:18 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantCommon shares without par value | 18,855 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-20-002268 · edgar.xml · nonDerivative · entry 1 Ginascol John F · CIK 0001778075 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,297 F1 · shares: These shares represent a performance-based restricted stock award under the Abbott Laboratories 2017 Incentive Stock Program. The award has a 3-year term, with no more than 1/3 of the award vesting in any one year upon Abbott reaching a minimum return on equity target. The award includes the right to have shares withheld for tax purposes. Read SEC document |
| June 03, 2019 Filed Jun 5, 2019 22:37 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantOption (right to buy) · Derivative | 62,725 | $0.00 Strike: $76.12 | $0.00 |
DisclosureSEC source: 0001179110-19-007233 · edgar.xml · derivative · entry 2 Ginascol John F · CIK 0001778075 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 62,725 Underlying: Common shares · 62,725 shares Expires 2029-06-02 F2 · security: Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 20,908 on June 3, 2020, 20,908 on June 3, 2021, and 20,909 on June 3, 2022. Read SEC document |
| June 03, 2019 Filed Jun 5, 2019 22:37 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantCommon shares without par value | 11,967 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-19-007233 · edgar.xml · nonDerivative · entry 1 Ginascol John F · CIK 0001778075 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,584 F1 · shares: These shares represent performance-based restricted stock awards under the Abbott Laboratories 2017 Incentive Stock Program. The awards have a 3-year term, with no more than 1/3 of the award vesting in any one year upon Abbott reaching a minimum return on equity target. The awards include the right to have stock withheld for tax purposes. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.